Canaccord Genuity reissued their buy rating on shares of LeMaitre Vascular Inc. (NASDAQ:LMAT) in a research note released on Friday. The brokerage currently has a $25.00 price target on the stock.

“Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Selecta Biosciences (NASDAQ: SELB) and Blueprint Medicines (NASDAQ: BPMC) | Analyst Ratings

window._wpemojiSettings = {“baseUrl”:”https:\/\/s.w.org\/images\/core\/emoji\/72×72\/”,”ext”:”.png”,”source”:{“concatemoji”:”http:\/\/www.analystratings.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=4.5.4″}};
!function(a,b,c){function d(a){var c,d,e,f=b.createElement(“canvas”),g=f.getContext&&f.getContext(“2d”),h=String.fromCharCode;if(!g||!g.fillText)return!1;switch(g.textBaseline=”top”,g.font=”600 32px Arial”,a){case”flag”:return g.fillText(h(55356,56806,55356,56826),0,0),f.toDataURL().length>3e3;case”diversity”:return g.fillText(h(55356,57221),0,0),c=g.getImageData(16,16,1,1).data,d=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],g.fillText(h(55356,57221,55356,57343),0,0),c=g.getImageData(16,16,1,1).data,e=c[0]+”,”+c[1]+”,”+c[2]+”,”+c[3],d!==e;case”simple”:return g.fillText(h(55357,56835),0,0),0!==g.getImageData(16,16,1,1).data[0];case”unicode8″:return g.fillText(h(55356,57135),0,0),0!==g.getImageData(16,16,1,1).data[0]}return!1}function e(a){var c=b.createElement(“script”);c.src=a,c.type=”text/javascript”,b.getElementsByTagName(“head”)[0].appendChild(c)}var f,g,h,i;for(i=Array(“simple”,”flag”,”unicode8″,”diversity”),c.supports={everything:!0,everythingExceptFlag:!0},h=0;h

var sampling_active = 0;
var sampling_rate = 100;
var do_request = false;

if ( !sampling_active ) {
do_request = true;
} else {
var num = Math.floor(Math.random() * sampling_rate) + 1;
do_request = ( 1 === num );
}

if ( do_request ) {

/* Create XMLHttpRequest object and set variables */
var xhr = ( window.XMLHttpRequest )
? new XMLHttpRequest()
: new ActiveXObject( “Microsoft.XMLHTTP” ),
url = ‘https://www.analystratings.com/wp-admin/admin-ajax.php’,
params = ‘action=update_views_ajax&token=99b8148e24&wpp_id=459982’;
/* Set request method and target URL */
xhr.open( “POST”, url, true );
/* Set request header */
xhr.setRequestHeader( “Content-type”, “application/x-www-form-urlencoded” );
/* Hook into onreadystatechange */
xhr.onreadystatechange = function() {
if ( 4 === xhr.readyState && 200 === xhr.status ) {
if ( window.console && window.console.log ) {
window.console.log( xhr.responseText );
}
}
};
/* Send request */
xhr.send( params );

}

(function(i,s,o,g,r,a,m){i[‘GoogleAnalyticsObject’]=r;i[r]=i[r]||function(){
(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
})(window,document,’script’,’//www.google-analytics.com/analytics.js’,’ga’);
ga(‘create’, ‘UA-55014446-1’, ‘auto’);
ga(‘send’, ‘pageview’);

window.$ = jQuery;

–>

Stock Market
Best Performing Analysts
Sectors

Basic Materials
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities

Most Popular
Contact Us

Home » Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Selecta Biosciences (NASDAQ: SELB) and Blueprint Medicines (NASDAQ: BPMC),” the firm’s analyst commented.

A number of other analysts also recently commented on the stock. Zacks Investment Research raised shares of LeMaitre Vascular from a hold rating to a strong-buy rating and set a $20.00 price objective on the stock in a report on Friday, July 29th. Barrington Research boosted their price objective on shares of LeMaitre Vascular from $18.50 to $20.00 and gave the stock an outperform rating in a report on Thursday, July 28th. Brean Capital boosted their price objective on shares of LeMaitre Vascular from $17.50 to $20.00 and gave the stock a buy rating in a report on Thursday, July 28th. Finally, Sidoti downgraded shares of LeMaitre Vascular from a buy rating to a neutral rating and set a $23.00 price objective on the stock. in a report on Thursday, September 22nd. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Buy and an average price target of $20.50.

Shares of LeMaitre Vascular (NASDAQ:LMAT) opened at 23.00 on Friday. LeMaitre Vascular has a 12-month low of $12.03 and a 12-month high of $24.36. The firm has a 50-day moving average of $20.56 and a 200 day moving average of $17.42. The stock has a market capitalization of $427.41 million, a price-to-earnings ratio of 41.89 and a beta of 0.58.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, October 26th. The company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.15 by $0.02. The business had revenue of $19 million for the quarter, compared to the consensus estimate of $22.20 million. LeMaitre Vascular had a net margin of 12.19% and a return on equity of 12.83%. The business’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.11 earnings per share. Equities analysts forecast that LeMaitre Vascular will post $0.58 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Monday, November 21st will be issued a $0.045 dividend. The ex-dividend date is Thursday, November 17th. This represents a $0.18 dividend on an annualized basis and a yield of 0.78%. LeMaitre Vascular’s payout ratio is 32.73%.

In related news, insider David B. Roberts sold 6,452 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $21.05, for a total value of $135,814.60. Following the completion of the sale, the insider now directly owns 69,793 shares in the company, valued at $1,469,142.65. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider David B. Roberts sold 33,548 shares of the business’s stock in a transaction that occurred on Thursday, September 15th. The shares were sold at an average price of $20.41, for a total transaction of $684,714.68. Following the completion of the sale, the insider now owns 79,793 shares of the company’s stock, valued at $1,628,575.13. The disclosure for this sale can be found here. 28.90% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in LMAT. JFS Wealth Advisors LLC bought a new stake in LeMaitre Vascular during the third quarter worth about $109,000. American International Group Inc. increased its stake in LeMaitre Vascular by 11.7% in the second quarter. American International Group Inc. now owns 7,775 shares of the company’s stock worth $111,000 after buying an additional 817 shares during the last quarter. Nationwide Fund Advisors increased its stake in LeMaitre Vascular by 6.7% in the second quarter. Nationwide Fund Advisors now owns 9,293 shares of the company’s stock worth $133,000 after buying an additional 580 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in LeMaitre Vascular by 19.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 11,330 shares of the company’s stock worth $162,000 after buying an additional 1,826 shares during the last quarter. Finally, The Manufacturers Life Insurance Company bought a new stake in LeMaitre Vascular during the third quarter worth about $197,000. Hedge funds and other institutional investors own 60.90% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

5 Day Chart for NASDAQ:LMAT

Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.